Efficacy of Taletrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC By Ogkologos - April 18, 2025 694 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an integrated analysis of the pivotal phase II regional TRUST-I and global TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma MOST POPULAR The art of practicing sustainable science April 22, 2021 From athlete to wig-maker: how cancer changed Maria’s destiny December 16, 2022 ACS’s Updated Cervical Cancer Screening Guidelines Explained September 18, 2020 EMA Recommends Extension of Indications for Venetoclax May 14, 2021 Load more HOT NEWS Mother Spent 14 Weeks Battling Breast Cancer Alone During COVID-19 Lockdown Talking With Your Doctor About Negative Emotions During Cancer Why do non-smokers face delays in getting a lung cancer diagnosis? Scientists Discover How Air Pollution May Trigger Lung Cancer in Never-Smokers...
